Pharmala Biotech Holdings Income Statement

Financials in millions CAD. Fiscal year is September - August.

Millions CAD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Revenue	0.89	0.61	1.04	0.53	0.08	-
Revenue Growth (YoY)	106.79%	-41.52%	94.60%	581.44%	-	-
Cost of Revenue	0.1	0.05	0.15	0.08	0	-
Gross Profit	0.79	0.55	0.89	0.45	0.08	-
Selling, General & Admin	1.4	1.26	0.71	1.15	0.71	0.36
Research & Development	0.2	0.24	0.13	-0.17	-	-
Operating Expenses	2.23	2.56	1.46	1.12	0.96	0.58
Operating Income	-1.44	-2.01	-0.58	-0.67	-0.88	-0.58
Earnings From Equity Investments	-	-0.02	-	-	-	-
Other Non Operating Income (Expenses)	-0.14	-0.11	-0.25	-0.11	-0.11	-0.06
EBT Excluding Unusual Items	-1.58	-2.14	-0.82	-0.78	-0.99	-0.64
Other Unusual Items	-0.07	-0.04	-	-	-	-3.13
Pretax Income	-1.63	-2.18	-0.82	-0.78	-0.99	-3.76
Net Income	-1.63	-2.18	-0.82	-0.78	-0.99	-3.76
Net Income to Common	-1.63	-2.18	-0.82	-0.78	-0.99	-3.76
Shares Outstanding (Basic)	105	100	89	85	80	30
Shares Outstanding (Diluted)	105	100	89	85	80	30
Shares Change (YoY)	12.44%	12.42%	4.79%	5.98%	163.82%	-
EPS (Basic)	-0.02	-0.02	-0.01	-0.01	-0.01	-0.12
EPS (Diluted)	-0.02	-0.02	-0.01	-0.01	-0.01	-0.12
Free Cash Flow	-0.92	-1.05	-0.32	-0.34	-0.63	-0.26
Free Cash Flow Per Share	-0.01	-0.01	-0.00	-0.00	-0.01	-0.01
Gross Margin	88.66%	91.22%	85.72%	85.36%	97.07%	-
Operating Margin	-161.56%	-331.97%	-55.73%	-125.74%	-1127.69%	-
Profit Margin	-183.55%	-359.25%	-79.55%	-146.58%	-1262.43%	-
Free Cash Flow Margin	-103.57%	-172.85%	-31.04%	-63.84%	-804.87%	-
EBITDA	-1.42	-1.96	-0.57	-0.67	-0.87	-0.58
EBITDA Margin	-159.13%	-	-55.15%	-125.42%	-	-
D&A For EBITDA	0.02	0.05	0.01	0	0.01	0
EBIT	-1.44	-2.01	-0.58	-0.67	-0.88	-0.58
EBIT Margin	-161.56%	-	-55.73%	-125.74%	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.